+86 137 2013 4139
+86 137 2013 4139
| CAS: | 2403703-30-8 | Cat No: | JKN03192 | Purity: | 98% |
Note: All products of the company are for scientific research only, and do not provide products and services for any individual
Product Description
| CAS | 2403703-30-8 | Cat No | JKN03192 | |
| Name | Zurletrectinib | |||
| Synonyms | Zurletrectinib | |||
| Smiles | C[C@H]1CNC(=O)NC2=C3N=C(C=CN3N=C2)N4C[C@H](C[C@@H]4C5=C(O1)N=CC(=C5)F)F | |||
| Chemical Name | (4S,6R,14S)-4,9-difluoro-14-methyl-13-oxa-2,11,16,18,21,22,25-heptazapentacyclo[17.5.2.02,6.07,12.022,26]hexacosa-1(25),7(12),8,10,19(26),20,23-heptaen-17-one | |||
| Formula | C19H19F2N7O2 | MWt | 415.4 | |
| Purity | 98% | Storage | Store at 4--8℃ | |
| Description | Zurletrectinib is an orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, zurletrectinib specifically targets and binds to TRK, TRK mutations and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC). This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance. | |||
Product Documents
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
